With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up ...

FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

GSK PLC closed 15.32% short of its 52-week high of £16.79, which the company reached on September 9th.

UK pharma major GSK is seeking US approval for Blenrep (belantamab mafodotin) in two multiple myeloma indications.

The usually sluggish FTSE 100 is having a surprisingly good year. But our writer feels there are still potential bargains ...

GSK's blood cancer drug, Blenrep, is under the U.S. Food and Drug Administration (USFDA) spotlight, as staff reviewers raised ...

AWS beleives AI agents will change how enterprises work and with its new Amazon Bedrock AgentCore, it hopes to make it easier ...

Recent health headlines include FDA's eye safety concerns over GSK's cancer drug, escalating malnutrition rates in Gaza ...

This summary highlights significant events in the health sector, including Johnson & Johnson's profit boost from Darzalex, safety concerns for GSK's cancer drug, refugee malnutrition in Gaza, KKR's ...

Anthropic has launched a powerful analytics dashboard for its Claude Code AI assistant, giving engineering leaders real-time insights into developer productivity, tool usage, and ROI on AI coding ...

A team of leading infectious disease scientists from academia and industry have been awarded £17.9 million to identify new ...

From my colleague Drew Joseph: Ahead of an advisory committee meeting Thursday focused on GSK’s multiple myeloma drug Blenrep, the FDA pointed to concerns about the high rates of eye issues that have ...